Literature DB >> 16553505

Do angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers decrease the risk of hospitalization secondary to community-acquired pneumonia? A nested case-control study.

Mahyar Etminan1, Bin Zhang, Mark Fitzgerald, James M Brophy.   

Abstract

STUDY
OBJECTIVE: As studies have shown that angiotensin-converting enzyme (ACE) inhibitors may lower the risk of developing pneumonia by increasing the cough reflex, we sought to explore the potential association between use of ACE inhibitors and the risk of hospitalization secondary to community-acquired pneumonia (CAP). To test this hypothesis further, we also looked at the risk for CAP in those taking angiotensin II receptor blockers (ARBs), as these drugs have a similar mechanism of action to that of ACE inhibitors but have minimal or no effect on the cough reflex. In addition, the putative protection against pneumonia may instead be related to general inhibition of the renin-angiotensin system.
DESIGN: Nested case-control study. DATA SOURCE: Universal Quebec, Canada, administrative health databases. PATIENTS: From a cohort of 47,148 patients with coronary artery disease who had a revascularization procedure between 1996 and 2000, 1666 patients with CAP and 33,315 time-matched control subjects (20 controls for each case) were identified.
MEASUREMENTS AND MAIN RESULTS: Conditional logistic regression analysis was used to estimate rate ratios, while controlling for potential confounders. No association was observed between patients receiving ACE inhibitors and hospitalization for CAP (rate ratio [RR] 0.98, 95% confidence interval [CI] 0.69-1.40). A similar lack of association was noted for those receiving ARBs (RR 1.02, 95% CI 0.70-1.49).
CONCLUSION: In this case-control study, no association was found between use of ACE inhibitors or ARBs and risk of hospitalization secondary to CAP. Future studies are necessary to explore this association further.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16553505     DOI: 10.1592/phco.26.4.479

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  8 in total

Review 1.  Diabetes, insulin, and development of acute lung injury.

Authors:  Shyoko Honiden; Michelle N Gong
Journal:  Crit Care Med       Date:  2009-08       Impact factor: 7.598

2.  Angiotensin-converting enzyme inhibitor use and pneumonia risk in community-dwelling older adults: results from a population-based case-control study.

Authors:  Sascha Dublin; Rod L Walker; Michael L Jackson; Jennifer C Nelson; Noel S Weiss; Lisa A Jackson
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-09-05       Impact factor: 2.890

Review 3.  Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis.

Authors:  Daniel Caldeira; Joana Alarcão; António Vaz-Carneiro; João Costa
Journal:  BMJ       Date:  2012-07-11

4.  Risk of hospitalization for community acquired pneumonia with renin-angiotensin blockade in elderly patients: a population-based study.

Authors:  Sachin Shah; Eric McArthur; Alexandra Farag; Michael Nartey; Jamie L Fleet; Greg A Knoll; S Joseph Kim; Amit X Garg; Arsh K Jain
Journal:  PLoS One       Date:  2014-10-29       Impact factor: 3.240

5.  Renin-angiotensin system antagonists and mortality due to pneumonia, influenza, and chronic lower respiratory disease in patients with hypertension.

Authors:  Heng-Xuan Cai; Chen-Chen Liang; Shan-Jie Wang; Jun-Chen Guo; Ye Wang; Bo Yu; Xue-Qin Gao; Shao-Hong Fang
Journal:  J Geriatr Cardiol       Date:  2022-07-28       Impact factor: 3.189

Review 6.  Use of ACE inhibitors and risk of community-acquired pneumonia: a review.

Authors:  Petros I Rafailidis; Dimitrios K Matthaiou; Ioannis Varbobitis; Matthew E Falagas
Journal:  Eur J Clin Pharmacol       Date:  2008-06       Impact factor: 3.064

7.  Pneumonia risk and use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers.

Authors:  Chia-Lin Liu; Wen-Yi Shau; Chia-Hsuin Chang; Chi-Shin Wu; Mei-Shu Lai
Journal:  J Epidemiol       Date:  2013-08-03       Impact factor: 3.211

Review 8.  Comparison of infection risks and clinical outcomes in patients with and without SARS-CoV-2 lung infection under renin-angiotensin-aldosterone system blockade: Systematic review and meta-analysis.

Authors:  Chang Chu; Shufei Zeng; Ahmed A Hasan; Carl-Friedrich Hocher; Bernhard K Krämer; Berthold Hocher
Journal:  Br J Clin Pharmacol       Date:  2020-12-18       Impact factor: 3.716

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.